Quantitation of human peptides and proteins via MS: Review of analytically validated assays

Bioanalysis

Volumn 6, Issue 13, 2014, Pages 1843-1857

  Chappell, Derek L ^a   Lassman, Michael E ^a   McAvoy, Thomas ^a   Lin, Mingxiang ^a   Spellman, Daniel S ^a   Laterza, Omar F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANGIOTENSIN I; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; AQUAPORIN 2; BIOLOGICAL MARKER; BRADYKININ; CALCITONIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INTERLEUKIN 21; ISOPROTEIN; MONOCLONAL ANTIBODY; MUCIN; NERVE GROWTH FACTOR; NONSPECIFIC ESTERASE; PARATHYROID HORMONE; PEPSIN A; PEPSINOGEN; PEPTIDE; PROTEIN; SOMATOMEDIN C; TAU PROTEIN; THYROGLOBULIN;

ANALYTIC METHOD; DRUG ABSORPTION; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; LIGAND BINDING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR DYNAMICS; PEPTIDE ANALYSIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN METABOLISM; REVIEW; VALIDATION PROCESS; BLOOD; CEREBROSPINAL FLUID; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOAFFINITY CHROMATOGRAPHY; METABOLISM; TANDEM MASS SPECTROMETRY;

ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; IMMUNOCHROMATOGRAPHY; PEPTIDES; PROTEINS; TANDEM MASS SPECTROMETRY;

EID: 84906702600     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.145     Document Type: Review

References (116)

1. Kitteringham NR, Jenkins RE, Lane CS, Elliott VL, Park BK. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(13), 1229-1239 (2009).
2. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell Proteomics 5(4), 573-588 (2006).
3. Fortin T, Salvador A, Charrier JP et al. Multiple reaction monitoring cubed for protein quantification at the low nanogram/milliliter level in nondepleted human serum. Anal. Chem. 81(22), 9343-9352 (2009).
4. Jaffuel A, Lemoine J, Aubert C et al. Optimization of liquid chromatography-multiple reaction monitoring cubed mass spectrometry assay for protein quantification: application to aquaporin-2 water channel in human urine. J. Chromatogr. A 1301, 122-130 (2013).
5. Shi T, Fillmore TL, Sun X et al. Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc. Natl Acad. Sci. USA 109(38), 15395-15400 (2012).
6. Shi T, Sun X, Gao Y et al. Targeted quantification of low ng/ ml level proteins in human serum without immunoaffinity depletion. J. Proteome Res 12(7), 3353-3361 (2013).
7. Rochat B, Kottelat E, McMullen J. The future key role of LC-high-resolution-MS analyses in clinical laboratories: a focus on quantification. Bioanalysis 4(24), 2939-2958 (2012).
8. Arnold DW, Needham SR. Micro-LC-MS/MS: the future of Bioanalysis Bioanalysis. 5(11), 1329-1331 (2013).
9. Christianson CC, Johnson CJ, Needham SR. The advantages of microflow LC-MS/MS compared with conventional HPLC-MS/MS for the analysis of methotrexate from human plasma. Bioanalysis 5(11), 1387-1396 (2013).
10. Tamvakopoulos C. Mass spectrometry for the quantification of bioactive peptides in biological fluids. Mass Spectrom. Rev. 26(3), 389-402 (2007).
11. Chappell DL, Lee AY, Castro-Perez J et al. An ultrasensitive method for the quantitation of active and inactive GLP-1 in human plasma via immunoaffinity LC-MS/MS. Bioanalysis 6(1), 33-42 (2014).
12. Zhu KY, Leung KW, Ting AK et al. Microfluidic chip based nano liquid chromatography coupled to tandem mass spectrometry for the determination of abused drugs and metabolites in human hair. Anal. Bioanal. Chem. 402(9), 2805-2815 (2012).
13. Broccardo CJ, Schauer KL, Kohrt WM, Schwartz RS, Murphy JP, Prenni JE. Multiplexed analysis of steroid hormones in human serum using novel microflow tile technology and LC-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 934, 16-21 (2013).
14. Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell Proteomics 6(12), 2212-2229 (2007).
15. Kuhn E, Whiteaker JR, Mani DR et al. Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol. Cell Proteomics 11(6), M111- (2012).
16. Whiteaker JR, Zhao L, Anderson L, Paulovich AG. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol. Cell Proteomics 9(1), 184-196 (2010).
17. Holst JJ. The physiology of glucagon-like peptide 1. Physiol. Rev. 87(4), 1409-1439 (2007).
18. Lame ME, Chambers EE, Blatnik M. Quantitation of amyloid beta peptides Abeta(1-38), Abeta(1-40), and Abeta(1-42) in human cerebrospinal fluid by ultraperformance liquid chromatography-tandem mass spectrometry. Anal. Biochem. 419(2), 133-139 (2011).
19. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics 1(11), 845-867 (2002).
20. van dB I, Sparidans RW, Schellens JH, Beijnen JH. Sensitive liquid chromatography/tandem mass spectrometry assay for absolute quantification of ITIH4-derived putative biomarker peptides in clinical serum samples. Rapid Commun. Mass Spectrom. 24(13), 1842-1850 (2010).
21. van dB I, Sparidans RW, Schellens JH, Beijnen JH. Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878(5-6), 590-602 (2010).
22. CSF Materials and Methods Working Groups. (2014).http://www.alz.org/ research/funding/global-biomarker-CSF-materials.asp
23. Whiteaker JR, Paulovich AG. Peptide immunoaffinity enrichment coupled with mass spectrometry for peptide and protein quantification. Clin. Lab. Med. 31(3), 385-396 (2011).
24. Nicol GR, Han M, Kim J et al. Use of an immunoaffinitymass spectrometry-based approach for the quantification of protein biomarkers from serum samples of lung cancer patients. Mol. Cell Proteomics 7(10), 1974-1982 (2008).
25. Ackermann BL. Understanding the role of immunoaffinitybased mass spectrometry methods for clinical applications. Clin. Chem. 58(12), 1620-1622 (2012).
26. Neubert H, Muirhead D, Kabir M, Grace C, Cleton A, Arends R. Sequential protein and peptide immunoaffinity capture for mass spectrometry-based quantification of total human beta-nerve growth factor. Anal. Chem. 85(3), 1719-1726 (2013).
27. Torsetnes SB, Lovbak SG, Claus C et al. Immunocapture and LC-MS/MS for selective quantification and differentiation of the isozymes of the biomarker neuronspecific enolase in serum. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 929, 125-132 (2013).
28. Wolf R, Rosche F, Hoffmann T, Demuth HU. Immunoprecipitation and liquid chromatographic-mass spectrometric determination of the peptide glucosedependent insulinotropic polypeptides GIP1-42 and GIP3-42 from human plasma samples. New sensitive method to analyze physiological concentrations of peptide hormones. J. Chromatogr. A 926(1), 21-27 (2001).
29. Miyachi A, Murase T, Yamada Y, Osonoi T, Harada K. Quantitative analytical method for determining the levels of gastric inhibitory polypeptides GIP1-42 and GIP3-42 in human plasma using LC-MS/MS/MS. J. Proteome Res. 12(6), 2690-2699 (2013).
30. Wolf R, Hoffmann T, Rosche F, Demuth HU. Simultaneous determination of incretin hormones and their truncated forms from human plasma by immunoprecipitation and liquid chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 803(1), 91-99 (2004).
31. Bystrom CE, Sheng S, Clarke NJ. Narrow mass extraction of time-of-flight data for quantitative analysis of proteins: determination of insulin-like growth factor-1. Anal. Chem. 83(23), 9005-9010 (2011).
32. Chappell DL, McAvoy T, Weiss B, Weiner R, Laterza OF. Development and validation of an ultra-sensitive method for the measurement of plasma renin activity in human plasma via LC-MS/MS. Bioanalysis 4(23), 2843-2850 (2012).
33. Morin LP, Mess JN, Garofolo F. Large-molecule quantification: sensitivity and selectivity head-to-head comparison of triple quadrupole with Q-TOF. Bioanalysis 5(10), 1181-1193 (2013).
34. Dillen L, Cuyckens F. High-resolution MS: first choice for peptide quantification? Bioanalysis 5(10), 1145-1148 (2013).
35. Dillen L, Cools W, Vereyken L et al. Comparison of triple quadrupole and high-resolution TOF-MS for quantification of peptides. Bioanalysis 4(5), 565-579 (2012).
36. Ramagiri S, Garofolo F. Large molecule bioanalysis using Q-TOF without predigestion and its data processing challenges. Bioanalysis 4(5), 529-540 (2012).
37. Oe T, Ackermann BL, Inoue K et al. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimers disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20(24), 3723-3735 (2006).
38. Ackermann BL, Berna MJ. Coupling immunoaffinity techniques with MS for quantitative analysis of lowabundance protein biomarkers. Expert Rev. Proteomics 4(2), 175-186 (2007).
39. Ewles M, Goodwin L. Bioanalytical approaches to analyzing peptides and proteins by LC-MS/MS. Bioanalysis 3(12), 1379-1397 (2011).
40. Gillette MA, Carr SA. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat. Methods 10(1), 28-34 (2013).
41. Shi T, Su D, Liu T et al. Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics. Proteomics 12(8), 1074-1092 (2012).
42. Kushnir MM, Rockwood AL, Roberts WL, Abraham D, Hoofnagle AN, Meikle AW. Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies. Clin. Chem. 59(6), 982-990 (2013).
43. Simon R, Girod M, Fonbonne C et al. Total ApoE and ApoE4 isoform assays in an Alzheimers disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides. Mol. Cell Proteomics 11(11), 1389-1403 (2012).
44. Lassman ME, McLaughlin TM, Somers EP et al. A rapid method for cross-species quantitation of apolipoproteins A1, B48 and B100 in plasma by ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 26(2), 101-108 (2012).
45. Kay R, Halsall DJ, Annamalai AK et al. A novel mass spectrometry-based method for determining insulin-like growth factor 1: assessment in a cohort of subjects with newly diagnosed acromegaly. Clin. Endocrinol. (Oxf.) 78(3), 424-430 (2013).
46. Hoofnagle AN, Becker JO, Oda MN, Cavigiolio G, Mayer P, Vaisar T. Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures. Clin. Chem. 58(4), 777-781 (2012).
47. Flood-Nichols SK, Tinnemore D, Wingerd MA et al. Longitudinal analysis of maternal plasma apolipoproteins in pregnancy: a targeted proteomics approach. Mol. Cell Proteomics 12(1), 55-64 (2013).
48. Agger SA, Marney LC, Hoofnagle AN. Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry. Clin. Chem. 56(12), 1804-1813 (2010).
49. Overgaard AJ, Hansen HG, Lajer M et al. Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy. Proteome Sci. 8, 4 (2010).
50. Moore RE, Navab M, Millar JS et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ. Res. 97(8), 763-771 (2005).
51. Callow MJ, Stoltzfus LJ, Lawn RM, Rubin EM. Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice. Proc. Natl Acad. Sci. USA 91(6), 2130-2134 (1994).
52. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J. Clin. Invest. 116(12), 3090-3100 (2006).
53. Chan L. Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins. J. Biol. Chem. 267(36), 25621-25624 (1992).
54. Zhou H, Hoek M, Yi P et al. Rapid detection and quantification of apolipoprotein L1 genetic variants and total levels in plasma by ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 27(23), 2639-2647 (2013).
55. Arsene CG, Henrion A, Diekmann N, Manolopoulou J, Bidlingmaier M. Quantification of growth hormone in serum by isotope dilution mass spectrometry. Anal. Biochem. 401(2), 228-235 (2010).
56. Domanski D, Percy AJ, Yang J et al. MRM-based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma. Proteomics 12(8), 1222-1243 (2012).
57. Barton C, Kay RG, Gentzer W, Vitzthum F, Pleasance S. Development of high-throughput chemical extraction techniques and quantitative HPLC-MS/MS (SRM) assays for clinically relevant plasma proteins. J. Proteome Res 9(1), 333-340 (2010).
58. Neubert H, Gale J, Muirhead D. Online high-flow peptide immunoaffinity enrichment and nanoflow LC-MS/MS: assay development for total salivary pepsin/pepsinogen. Clin. Chem. 56(9), 1413-1423 (2010).
59. Palandra J, Finelli A, Zhu M, Masferrer J, Neubert H. Highly specific and sensitive measurements of human and monkey interleukin 21 using sequential protein and tryptic peptide immunoaffinity LC-MS/MS. Anal. Chem. 85(11), 5522-5529 (2013).
60. Lassman ME, McLaughlin TM, Somers EP et al. A rapid method for cross-species quantitation of apolipoproteins A1, B48 and B100 in plasma by ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 26(2), 101-108 (2012).
61. Kay RG, Gregory B, Grace PB, Pleasance S. The application of ultra-performance liquid chromatography/tandem mass spectrometry to the detection and quantitation of apolipoproteins in human serum. Rapid Commun. Mass Spectrom. 21(16), 2585-2593 (2007).
62. Hoofnagle AN, Becker JO, Wener MH, Heinecke JW. Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin. Chem. 54(11), 1796-1804 (2008).
63. Lindberg C, van Geest M, Lindberg H, Kjellstrom S. Liquid chromatography-tandem mass spectrometry approach for quantification of mucins from sputum using 13C,15Nlabeled peptides as internal standards. Anal. Biochem. 434(1), 84-92 (2013).
64. Palandra J, Finelli A, Zhu M, Masferrer J, Neubert H. Highly specific and sensitive measurements of human and monkey interleukin 21 using sequential protein and tryptic peptide immunoaffinity LC-MS/MS. Anal. Chem. 85(11), 5522-5529 (2013).
65. McAvoy T, Lassman ME, Spellman DS et al. Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry. Clin. Chem. 60(4), 683-689 (2014).
66. Torsetnes SB, Lovbak SG, Claus C et al. Immunocapture and LC-MS/MS for selective quantification and differentiation of the isozymes of the biomarker neuron-specific enolase in serum. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 929, 125-132 (2013).
67. Kumar V, Barnidge DR, Chen LS et al. Quantification of serum 1-84 parathyroid hormone in patients with hyperparathyroidism by immunocapture in situ digestion liquid chromatography-tandem mass spectrometry. Clin. Chem. 56(2), 306-313 (2010).
68. Li Q. Advances in protein turnover analysis at the global level and biological insights. Mass Spectrom. Rev. 29(5), 717-736 (2010).
69. Dauner M, Sauer U. GC-MS analysis of amino acids rapidly provides rich information for isotopomer balancing. Biotechnol. Prog. 16(4), 642-649 (2000).
70. Jaleel A, Nehra V, Persson XM, Boirie Y, Bigelow M, Nair KS. In vivo measurement of synthesis rate of multiple plasma proteins in humans. Am. J. Physiol. Endocrinol. Metab. 291(1), E190-E197 (2006).
71. Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer EJ. Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J. Clin. Invest. 85(3), 804-811 (1990).
72. Bateman RJ, Munsell LY, Chen X, Holtzman DM, Yarasheski KE. Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. J. Am. Soc. Mass Spectrom. 18(6), 997-1006 (2007).
73. Pratt JM, Petty J, Riba-Garcia I et al. Dynamics of protein turnover, a missing dimension in proteomics. Mol. Cell Proteomics 1(8), 579-591 (2002).
74. Tomazela DM, Patterson BW, Hanson E et al. Measurement of human surfactant protein-B turnover in vivo from tracheal aspirates using targeted proteomics. Anal. Chem. 82(6), 2561-2567 (2010).
75. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12(7), 856-861 (2006).
76. Mawuenyega KG, Sigurdson W, Ovod V et al. Decreased clearance of CNS beta-amyloid in Alzheimers disease. Science 330(6012), 1774 (2010).
77. Bateman RJ, Siemers ER, Mawuenyega KG et al. A gammasecretase inhibitor decreases amyloid-beta production in the central nervous system. Ann. Neurol. 66(1), 48-54 (2009).
78. Zhou H, Castro-Perez J, Lassman ME et al. Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry. Rapid Commun. Mass Spectrom. 27(12), 1294-1302 (2013).
79. Wildsmith KR, Basak JM, Patterson BW et al. In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. PLoS ONE 7(6), e38013 (2012).
80. Belloto E, Diraison F, Basset A, Allain G, Abdallah P, Beylot M. Determination of protein replacement rates by deuterated water: validation of underlying assumptions. Am. J. Physiol. Endocrinol. Metab. 292(5), E1340-E1347 (2007).
81. Conway JP, Johns DG, Wang SP et al. Measuring H(2)(18) O tracer incorporation on a QQQ-MS platform provides a rapid, transferable screening tool for relative protein synthesis. J. Proteome Res. 11(3), 1591-1597 (2012).
82. Kasumov T, Willard B, Li L et al. 2H2O-based high-density lipoprotein turnover method for the assessment of dynamic high-density lipoprotein function in mice. Arterioscler. Thromb. Vasc. Biol. 33(8), 1994-2003 (2013).
83. Li L, Willard B, Rachdaoui N et al. Plasma proteome dynamics: analysis of lipoproteins and acute phase response proteins with 2H2O metabolic labeling. Mol. Cell Proteomics 11(7), M111- (2012).
84. Rachdaoui N, Austin L, Kramer E et al. Measuring proteome dynamics in vivo: as easy as adding water.? Mol. Cell Proteomics 8(12), 2653-2663 (2009).
85. Previs SF, McLaren DG, Wang SP et al. New methodologies for studying lipid synthesis and turnover: looking backwards to enable moving forwards. Biochim. Biophys. Acta 1842(3), 402-413 (2013).
86. Tomazela DM, Patterson BW, Hanson E. Measurement of human surfactant protein-B turnover in vivo from tracheal aspirates using targeted proteomics. Anal. Chem. 82(6), 2561-2567 (2010).
87. Lee AY, Yates NA, Ichetovkin M et al. Measurement of fractional synthetic rates of multiple protein analytes by triple quadrupole mass spectrometry. Clin. Chem. 58(3), 619-627 (2012).
88. Lassman ME, McAvoy T, Lee AYH et al. A practical method to enable the measurement of protein kinetics for lowabundance proteins. Clin. Chem. (2014).
89. Hinkson IV, Elias JE. The dynamic state of protein turnover: its about time. Trends Cell Biol. 21(5), 293-303 (2011).
90. Liebler DC, Zimmerman LJ. Targeted quantitation of proteins by mass spectrometry. Biochemistry 52(22), 3797-3806 (2013).
91. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10(5), 301-316 (2010).
92. Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J. Pharm. Sci. 97(7), 2426-2447 (2008).
93. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 9(10), 767-774 (2010).
94. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23(9), 1073-1078 (2005).
95. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 84(5), 548-558 (2008).
96. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10(5), 317-327 (2010).
97. Beck A, Wagner-Rousset E, Bussat MC et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr. Pharm. Biotechnol. 9(6), 482-501 (2008).
98. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 10(5), 345-352 (2010).
99. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885-1900 (2003).
100. Damen CW, Schellens JH, Beijnen JH. Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies. Hum. Antibodies 18(3), 47-73 (2009).
101. Hoofnagle AN, Wener MH. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J. Immunol. Methods 347(1-2), 3-11 (2009).
102. Ezan E, Bitsch F. Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies. Bioanalysis 1(8), 1375-1388 (2009).
103. Dubois M, Becher F, Herbet A, Ezan E. Immuno-mass spectrometry assay of EPI-HNE4, a recombinant protein inhibitor of human elastase. Rapid Commun. Mass Spectrom. 21(3), 352-358 (2007).
104. Dubois M, Fenaille F, Clement G et al. Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. Anal. Chem. 80(5), 1737-1745 (2008).
105. Hagman C, Ricke D, Ewert S, Bek S, Falchetto R, Bitsch F. Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry. Anal. Chem. 80(4), 1290-1296 (2008).
106. Heudi O, Barteau S, Zimmer D et al. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. Anal. Chem. 80(11), 4200-4207 (2008).
107. Ji C, Sadagopan N, Zhang Y, Lepsy C. A universal strategy for development of a method for absolute quantification of therapeutic monoclonal antibodies in biological matrices using differential dimethyl labeling coupled with ultra performance liquid chromatography-tandem mass spectrometry. Anal. Chem. 81(22), 9321-9328 (2009).
108. Lesur A, Varesio E, Hopfgartner G. Protein quantification by MALDI-selected reaction monitoring mass spectrometry using sulfonate derivatized peptides. Anal. Chem. 82(12), 5227-5237 (2010).
109. Mesmin C, Fenaille F, Ezan E, Becher F. MS-based approaches for studying the pharmacokinetics of protein drugs. Bioanalysis 3(5), 477-480 (2011).
110. van dB I, Niessen WM, van Dongen WD. Bioanalytical LC- MS/MS of protein-based biopharmaceuticals. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 929, 161-179 (2013).
111. Ezan E, Dubois M, Becher F. Bioanalysis of recombinant proteins and antibodies by mass spectrometry. Analyst 134(5), 825-834 (2009).
112. Liu H, Manuilov AV, Chumsae C, Babineau ML, Tarcsa E. Quantitation of a recombinant monoclonal antibody in monkey serum by liquid chromatography-mass spectrometry. Anal. Biochem. 414(1), 147-153 (2011).
113. Halquist MS, Thomas KH. Quantitative liquid chromatography tandem mass spectrometry analysis of macromolecules using signature peptides in biological fluids. Biomed. Chromatogr. 25(1-2), 47-58 (2011).
114. Duan X, Abuqayyas L, Dai L, Balthasar JP, Qu J. Highthroughput method development for sensitive, accurate, and reproducible quantification of therapeutic monoclonal antibodies in tissues using orthogonal array optimization and nano liquid chromatography/selected reaction monitoring mass spectrometry. Anal. Chem. 84(10), 4373-4382 (2012).
115. Arsene CG, Ohlendorf R, Burkitt W et al. Protein quantification by isotope dilution mass spectrometry of proteolytic fragments: cleavage rate and accuracy. Anal. Chem. 80(11), 4154-4160 (2008).
116. Furlong MT, Ouyang Z, Wu S et al. A universal surrogate peptide to enable LC-MS/MS bioanalysis of a diversity of human monoclonal antibody and human Fc-fusion protein drug candidates in pre-clinical animal studies. Biomed. Chromatogr. 26(8), 1024-1032 (2012).